TIMEPIDIUM BROMIDE

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C17H22NOS2.Br
Molecular Weight	400.397
Optical Activity	( + / - )
Defined Stereocenters	0 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Br-].COC1CC(C[N+](C)(C)C1)=C(C2=CC=CS2)C3=CC=CS3

InChI

InChIKey=QTSXMEPZSHLZFF-UHFFFAOYSA-M

InChI=1S/C17H22NOS2.BrH/c1-18(2)11-13(10-14(12-18)19-3)17(15-6-4-8-20-15)16-7-5-9-21-16;/h4-9,14H,10-12H2,1-3H3;1H/q+1;/p-1

HIDE SMILES / InChI

Molecular Formula	C17H22NOS2
Molecular Weight	320.493
Charge	1
Count

Stereochemistry	MIXED
Additional Stereochemistry	No
Defined Stereocenters	0 / 2
E/Z Centers	0
Optical Activity	( + / - )

Molecular Formula	BrH
Molecular Weight	80.912
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7262709 | https://www.ncbi.nlm.nih.gov/pubmed/10374898

Timepidium bromide is a quaternary ammonium antimuscarinic used for the symptomatic treatment of visceral spasms. It is a muscarinic antagonist.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Muscarinic acetylcholine receptor M1 168 Target ID: CHEMBL216 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10374898	Antagonist 2849	34.0 nM [Ki]
Muscarinic acetylcholine receptor M2 121 Target ID: CHEMBL211 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10374898	Antagonist 2849	7.7 nM [Ki]
Muscarinic acetylcholine receptor M3 160 Target ID: CHEMBL245 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10374898	Antagonist 2849	31.0 nM [Ki]
Muscarinic acetylcholine receptor M4 87 Target ID: CHEMBL1821 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10374898	Antagonist 2849	18.0 nM [Ki]
Muscarinic acetylcholine receptor M5 63 Target ID: CHEMBL2035 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10374898	Antagonist 2849	11.0 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Visceral spasms 6 Sources: http://en.pharmacodia.com/web/drug/1_11398.html https://www.ncbi.nlm.nih.gov/pubmed/700518	Primary		Approved 8583	Sesden Approved Use Visceral spasms

Doses

Dose	Population	Adverse events
15 mg single, intravenous Highest studied dose Dose: 15 mg Route: intravenous Route: single Dose: 15 mg Sources: https://pubmed.ncbi.nlm.nih.gov/3436156/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/3436156/	Sources: https://pubmed.ncbi.nlm.nih.gov/3436156/
30 mg 3 times / day multiple, oral Recommended Dose: 30 mg, 3 times / day Route: oral Route: multiple Dose: 30 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/12361147/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/12361147/	Disc. AE: Eosinophilic pustular folliculitis... AEs leading to discontinuation/dose reduction: Eosinophilic pustular folliculitis Sources: https://pubmed.ncbi.nlm.nih.gov/12361147/

AEs

AE	Significance	Dose	Population
Eosinophilic pustular folliculitis	Disc. AE	30 mg 3 times / day multiple, oral Recommended Dose: 30 mg, 3 times / day Route: oral Route: multiple Dose: 30 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/12361147/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/12361147/

PubMed

Title	Date	PubMed
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.	2010-12	21818443
Multiple granulomatous inflammation in the minor salivary glands: a proposed new entity, allergic granulomatous sialadenitis.	2004-11	15533228
Eosinophilic pustular folliculitis induced by allopurinol and timepidium bromide.	2002	12361147

Patents

Sample Use Guides

In Vivo Use Guide

Adult Dosage: 30mg x 3 times a day.

Route of Administration: Oral

In Vitro Use Guide

Timepidium inhibited dose-dependently the contraction of isolated guinea pig gallbladder evoked by stimulation at 5 Hz. The mean dose producing a 50 % decrease in the electrically induced contraction (ID50 value) was 2.4 x 10(-8) g/ml. Timepidium (10(-6) g/ml) also inhibited, for the most part, the contraction induced by stimulation at 30 Hz.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:17:57 GMT 2025` Edited by `admin` on `Mon Mar 31 18:17:57 GMT 2025`
Record UNII	8R9E4766V4
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TIMEPIDIUM BROMIDE

Official Name

English

TIMEPIDIUM BROMIDE [MI]

Preferred Name

English

3-(DI-2-THIENYLMETHYLENE)-5-METHOXY-1,1-DIMETHYL-PIPERIDINIUM BROMIDE

Systematic Name

English

Timepidium bromide [WHO-DD]

Common Name

English

TIMEPIDIUM BROMIDE [MART.]

Common Name

English

timepidium bromide [INN]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QA03AB19